scholarly article | Q13442814 |
P356 | DOI | 10.1016/0090-8258(91)90255-4 |
P953 | full work available at URL | https://api.elsevier.com/content/article/PII:0090825891902554?httpAccept=text/plain |
https://api.elsevier.com/content/article/PII:0090825891902554?httpAccept=text/xml | ||
P698 | PubMed publication ID | 1851126 |
P2093 | author name string | C. Cavallo | |
D. Meehan | |||
J. Wimalasena | |||
P2860 | cites work | Elevated levels of CA-125 in serum of patients suffering from ovarian hyperstimulation syndrome | Q70359483 |
Functioning ovarian tumors in postmenopausal women | Q70772992 | ||
Investigation of Binding Sites for Follicle-Stimulating Hormone and Chorionic Gonadotropin in Human Ovarian Cancers* | Q72386176 | ||
Multiple biochemical markers in patients with gynecologic malignancies | Q72640920 | ||
An immunohistochemical study of the incidence and significance of human chorionic gonadotrophin synthesis by epithelial ovarian neoplasms | Q72709062 | ||
Steroid synthesis in cystadenocarcinoma of the ovaries | Q72752693 | ||
Steroid receptors and response of ovarian cancer to hormones in vitro | Q72814566 | ||
Gonadotropic hormone binding to human ovarian tumors | Q72912095 | ||
LH(hCG) Receptor in Benign and Malignant Tumors of Human Ovary | Q72913615 | ||
Some observations on the effect of a GnRH analog in ovarian cancer | Q93519708 | ||
A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid | Q26778512 | ||
Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis | Q34055956 | ||
A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer | Q34254918 | ||
An immunohistochemical study of the incidence and significance of human gonadotrophin and prolactin binding sites in normal and neoplastic human ovarian tissue | Q36027003 | ||
Cancer antigen 125, tissue polypeptide antigen, carcinoembryonic antigen, and beta-chain human chorionic gonadotropin as serum markers of epithelial ovarian carcinoma | Q41251384 | ||
CA-125 serum concentrations during the menstrual cycle | Q41879833 | ||
Characteristics of cell lines established from a mixed mesodermal tumor of the human ovary. Carcinomatous cells are changeable to sarcomatous cells | Q42813086 | ||
Human chorionic gonadotropin, follicle-stimulating hormone, and luteinizing hormone in patients with epithelial ovarian carcinoma | Q44026933 | ||
Androstenedione production by malignant epithelial ovarian tumors. | Q51802553 | ||
Plasma progesterone and androstenedione in relation to changes in tumor volume and recurrence in women with ovarian carcinoma. | Q51815715 | ||
Plasma 20 alpha-OH-progesterone in women with malignant epithelial 'non-endocrine' ovarian tumors. | Q51832174 | ||
Progesterone as a possible tumor marker for "nonendocrine" ovarian malignant tumors. | Q51852197 | ||
Aromatization of testosterone by epithelial tumor cells cultured from patients with ovarian carcinoma | Q67949611 | ||
Combination assay of CA125, TPA, IAP, CEA, and ferritin in serum for ovarian cancer | Q68519063 | ||
Use of indium-111-labeled OC-125 monoclonal antibody in the detection of ovarian cancer | Q68827020 | ||
Leuprolide acetate in the treatment of refractory or persistent epithelial ovarian cancer | Q69172854 | ||
Localization of gonadotropin binding sites in human ovarian neoplasms | Q69357943 | ||
Androgen and estrogen secretion by normal and neoplastic ovaries in premenopausal women | Q69577255 | ||
Correlation of aromatase activity and steroid receptors in human ovarian carcinoma | Q70159973 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | oncology | Q162555 |
ovarian cancer | Q172341 | ||
P304 | page(s) | 56-63 | |
P577 | publication date | 1991-04-01 | |
P1433 | published in | Gynecologic Oncology | Q5625182 |
P1476 | title | Human epithelial ovarian cancer cell steroid secretion and its control by gonadotropins | |
P478 | volume | 41 |
Q92344331 | Dietary Glycotoxins, Advanced Glycation End Products, Inhibit Cell Proliferation and Progesterone Secretion in Ovarian Granulosa Cells and Mimic PCOS-like Symptoms |
Q40690543 | Epidemiology, etiology, and fertility drugs in ovarian epithelial carcinoma: where are we today? |
Q41457706 | Estrogen action in human ovarian cancer |
Q36790475 | Gonadotropins activate oncogenic pathways to enhance proliferation in normal mouse ovarian surface epithelium. |
Q35683646 | Growth regulation of ovarian cancer. |
Q71031979 | HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: lovastatin specifically targets P-glycoprotein-expressing cells |
Q33541940 | Hormonal interactions in ovarian cancer |
Q35068355 | Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone |
Q73932015 | Luteinizing hormone in peritoneal and ovarian cyst fluids: a predictor of ovarian carcinoma |
Q28371622 | Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells |
Q57267084 | Microtubule-interfering Agents Activate c-Jun N-terminal Kinase/Stress-activated Protein Kinase through Both Ras and Apoptosis Signal-regulating Kinase Pathways |
Q40869257 | The biology of ovarian cancer development. |
Q71816408 | The myometrium of postmenopausal women produces prolactin in response to human chorionic gonadotropin and α-subunit in vitro |